Patient Access Insights

An overview of the US healthcare market and the impact of the new administration

The first in our international series, focused on different healthcare landscapes around the world starting with the US.
Request this webinar

An overview of the US healthcare market and the impact of the new administration

Request this webinar

Originally broadcast: Wednesday 17th February 2021

Duration: 60 minutes. Available to watch on demand

Learning objectives:

  •  Explain how the US system works and who is responsible for making and informing market access decisions

  •  How to enter the US market using Europe as a frame of reference

  •  Understand the impact of the new administration and what to watch out for in 2021 / 2022

Who would benefit from registering to attend this webinar:

Market Access professionals seeking to learn about the US healthcare landscape.

The job functions that will benefit most include:

• Heads of Market Access

• Managing Directors

• Country Managers

• Chief Executives

• Health Economists

• Medical Directors

• Commercial Directors

• Policy Officers/Executives

• Marketing Directors

• Policy Advisors


Matt Sarnes

Matt Sarnes, Senior Vice President, Strategy & New Business Development, Xcenda

Matt Sarnes, PharmD, is Senior Vice President of Strategy & New Business Development at Xcenda, helping manufacturers develop innovative commercialization strategies and tactics for both pipeline and in-line products to overcome barriers to product access and improve patient care. Over his 20+ year career, he has used his deep expertise in market access, health economics, reimbursement, quality improvement, marketing, and distribution strategy to address some of healthcare’s biggest challenges. He has authored more than 50 scientific articles as well as book chapters on healthcare technology valuation and has spoken at many leading industry conferences.

Dr. Sarnes received his Doctor of Pharmacy from the University of Pittsburgh, and post-doctoral training in ambulatory care and outcomes research from Healthcore, Inc. and the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia.

Jennifer Snow

Jennifer Snow, Vice President of Reimbursement Policy Insights, Xcenda

Jennifer Snow, MPH, is the Vice President of Reimbursement Policy Insights and keeps clients and stakeholders informed on the latest legislative and regulatory updates and their commercial impact. Her team analyses the healthcare environment and provides strategic guidance on how to best navigate challenges to patient coverage and access. Ms. Snow is a subject matter expert on the Affordable Care Act, quality measures, medication adherence and federal health programmes, particularly the Medicare Prescription Drug Benefit (Part D). Ms. Snow holds an M.P.H. from the University of North Carolina-Chapel Hill and a B.S. in Russian from Georgetown University.

Christian Hill

Christian Hill, CEO, MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52